Therapeutics News

Chronic use of cannabinoid derivatives led to a significant increase in cannabinoid hyperemesis syndrome, characterized by episodes of severe nausea and cyclical vomiting, the symptoms of which improve with cannabis cessation, as well as cannabinoid dependency.

WASHINGTON – Amantadine, which is used to treat influenza type A, Parkinson’s disease, muscle fatigue, muscle movement disorders and multiple sclerosis off-label, may cause corneal edema resulting from endothelial loss, according to a poster presented here at Optometry’s Meeting.

A review of the literature evaluating the effects of cyclosporine (CsA) ophthalmic emulsion 0.05% as a treatment for dry eye found that the drug provides effective relief of symptoms.

A dexamethasone/povidone-iodine ophthalmic suspension may be appropriate treatment for adenoviral conjunctivitis in adults, according to researchers at the Association for Research and Vision in Ophthalmology annual meeting.

WASHINGTON – Paul M. Karpecki, OD, FAAO, reported on new and up-and-coming ocular therapeutics at a continuing education session here at Optometry’s Meeting.

In topical antiglaucoma therapy, the main factors impacting ocular surface disease were drops with preservatives, longer treatment duration and older age, according to research in the European Journal of Ophthalmology.

The combined clinical evidence from five trials supports the U.S. FDA approval of lifitegrast as a first-in-class medication for treating all signs and symptoms of dry eye disease, according to researchers at the Association of Research in Vision and Ophthalmology annual meeting.

Teva Pharmaceutical Ind. has launched a generic version of Pataday, the company announced in a press release.

PARx Solutions, a company that helps eye care prescribers get preauthorization from insurance companies, has upgraded its platform by adding features to better aid prescribers, according to information from PARx Solutions

Reproducible, statistically significant data shows that lifitegrast improves the signs and symptoms of dry eye, especially in the mild to moderate forms, along with a favorable safety profile, based on a literature review of the phase 2 and phase 3 OPUS studies.